Pomalidomide: a new IMiD with remarkable activity in both multiple myeloma and myelofibrosis.

Suppr

超能文献

作者信息

Lacy Martha Q, Rajkumar S Vincent

机构信息

Division of Hematology, Mayo Clinic, Rochester, MN 55905.

出版信息

Am J Hematol. 2010 Feb;85(2):95-6. doi: 10.1002/ajh.21610.

DOI:10.1002/ajh.21610

PMID:20095057

Abstract

摘要

相似文献

Pomalidomide: a new IMiD with remarkable activity in both multiple myeloma and myelofibrosis.

Am J Hematol. 2010 Feb;85(2):95-6. doi: 10.1002/ajh.21610.

Lenalidomide and thalidomide: an evolving paradigm for the management of multiple myeloma.

Semin Hematol. 2005 Oct;42(4 Suppl 4):S1-2. doi: 10.1053/j.seminhematol.2005.10.005.

Pomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data.

Expert Rev Anticancer Ther. 2014 May;14(5):499-510. doi: 10.1586/14737140.2014.906904. Epub 2014 Apr 17.

[Pomalidomide for multiple myeloma].

Bull Cancer. 2017 Sep;104(9):707-713. doi: 10.1016/j.bulcan.2017.04.005. Epub 2017 Jun 2.

[IMiDs in hematology].

Bull Cancer. 2011 Aug;98(8):879-87. doi: 10.1684/bdc.2011.1404.

Pomalidomide (Pomalyst) for multiple myeloma.

Med Lett Drugs Ther. 2015 Apr 27;57(1467):e66-7.

Novel immunomodulatory compounds in multiple myeloma.

Expert Opin Investig Drugs. 2013 Feb;22(2):207-15. doi: 10.1517/13543784.2013.749235. Epub 2012 Dec 25.

Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy.

Oncogene. 2013 Sep 5;32(36):4191-202. doi: 10.1038/onc.2012.599. Epub 2013 Jan 14.

Thalidomide and lenalidomide in multiple myeloma.

Best Pract Res Clin Haematol. 2006;19(4):769-80. doi: 10.1016/j.beha.2006.06.006.

[Thalidomide: mechanisms of action and new insights in hematology].

Rev Med Interne. 2005 Feb;26(2):119-27. doi: 10.1016/j.revmed.2004.06.017.

引用本文的文献

Ubiquitin-conjugating enzyme UBE2N modulates proteostasis in immunoproteasome-positive acute myeloid leukemia.

J Clin Invest. 2025 May 15;135(10). doi: 10.1172/JCI184665.

Efficient Synthesis of Immunomodulatory Drug Analogues Enables Exploration of Structure-Degradation Relationships.

ChemMedChem. 2018 Aug 10;13(15):1508-1512. doi: 10.1002/cmdc.201800271. Epub 2018 Jul 4.

Targeting ubiquitination for cancer therapies.

Future Med Chem. 2015;7(17):2333-50. doi: 10.4155/fmc.15.148. Epub 2015 Dec 2.

Profile of pomalidomide and its potential in the treatment of myelofibrosis.

Ther Clin Risk Manag. 2015 Apr 2;11:549-56. doi: 10.2147/TCRM.S69211. eCollection 2015.

A sensitive and robust HPLC assay with fluorescence detection for the quantification of pomalidomide in human plasma for pharmacokinetic analyses.

J Pharm Biomed Anal. 2014 Apr;92:63-8. doi: 10.1016/j.jpba.2014.01.001. Epub 2014 Jan 9.

The rise, fall and subsequent triumph of thalidomide: lessons learned in drug development.

Ther Adv Hematol. 2011 Oct;2(5):291-308. doi: 10.1177/2040620711413165.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Pomalidomide: a new IMiD with remarkable activity in both multiple myeloma and myelofibrosis.

Am J Hematol. 2010 Feb;85(2):95-6. doi: 10.1002/ajh.21610.

Lenalidomide and thalidomide: an evolving paradigm for the management of multiple myeloma.

Semin Hematol. 2005 Oct;42(4 Suppl 4):S1-2. doi: 10.1053/j.seminhematol.2005.10.005.

Pomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data.

Expert Rev Anticancer Ther. 2014 May;14(5):499-510. doi: 10.1586/14737140.2014.906904. Epub 2014 Apr 17.

[Pomalidomide for multiple myeloma].

Bull Cancer. 2017 Sep;104(9):707-713. doi: 10.1016/j.bulcan.2017.04.005. Epub 2017 Jun 2.

[IMiDs in hematology].

Bull Cancer. 2011 Aug;98(8):879-87. doi: 10.1684/bdc.2011.1404.

Pomalidomide (Pomalyst) for multiple myeloma.

Med Lett Drugs Ther. 2015 Apr 27;57(1467):e66-7.

Novel immunomodulatory compounds in multiple myeloma.

Expert Opin Investig Drugs. 2013 Feb;22(2):207-15. doi: 10.1517/13543784.2013.749235. Epub 2012 Dec 25.

Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy.

Oncogene. 2013 Sep 5;32(36):4191-202. doi: 10.1038/onc.2012.599. Epub 2013 Jan 14.

Thalidomide and lenalidomide in multiple myeloma.

Best Pract Res Clin Haematol. 2006;19(4):769-80. doi: 10.1016/j.beha.2006.06.006.

[Thalidomide: mechanisms of action and new insights in hematology].

Rev Med Interne. 2005 Feb;26(2):119-27. doi: 10.1016/j.revmed.2004.06.017.

引用本文的文献

Ubiquitin-conjugating enzyme UBE2N modulates proteostasis in immunoproteasome-positive acute myeloid leukemia.

J Clin Invest. 2025 May 15;135(10). doi: 10.1172/JCI184665.

Efficient Synthesis of Immunomodulatory Drug Analogues Enables Exploration of Structure-Degradation Relationships.

ChemMedChem. 2018 Aug 10;13(15):1508-1512. doi: 10.1002/cmdc.201800271. Epub 2018 Jul 4.

Targeting ubiquitination for cancer therapies.

Future Med Chem. 2015;7(17):2333-50. doi: 10.4155/fmc.15.148. Epub 2015 Dec 2.

Profile of pomalidomide and its potential in the treatment of myelofibrosis.

Ther Clin Risk Manag. 2015 Apr 2;11:549-56. doi: 10.2147/TCRM.S69211. eCollection 2015.

A sensitive and robust HPLC assay with fluorescence detection for the quantification of pomalidomide in human plasma for pharmacokinetic analyses.

J Pharm Biomed Anal. 2014 Apr;92:63-8. doi: 10.1016/j.jpba.2014.01.001. Epub 2014 Jan 9.

The rise, fall and subsequent triumph of thalidomide: lessons learned in drug development.

Ther Adv Hematol. 2011 Oct;2(5):291-308. doi: 10.1177/2040620711413165.